BIO
XNYS
Market cap9.65bUSD
Nov 20, Last price
358.90USD
1D
-2.34%
1Q
-5.56%
Jan 2017
96.89%
Name
Bio Rad Laboratories Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Related entities
Subsidiaries (2)
BIO RAD LABORATORIES MANUFACTURE AND TRADE OF MEDICAL EQUIPMENT SINGLE MEMBER LIMITED LIABILITY COPANY
Bio - Rad Laboratories Gesellschaft mit beschränkter Haftung
Key people
Norman Schwartz
Chairman of the Board, Chief Executive Officer · since 2024
President, Chief Operating Officer · since 2024
Roop Lakkaraju
Chief Financial Officer, Executive Vice President · since 2024
James Barry
Executive Vice President, President - Life Science Group · since 2024
Michael Crowley
Executive Vice President - Global Commercial Operations · since 2014
Eva Anette Engelhardt
Executive Vice President, President of Clinical Diagnostics Group · since 2024
Courtney Enloe
Executive Vice President, General Counsel, Secretary · since 2024
Sedat Evran
Executive Vice President - Global Supply Chain · since 2023
Rajat Mehta
Executive Vice President - Global Commercial Operations · since 2025
Colleen Corey
Executive Vice President, Global Human Resources · since 2019
Allison Schwartz
Director · since 2022
Independent Director · since 2017
Lead Independent Director · since 2017
Independent Director · since 2017
Arnold Pinkston
Independent Director · since 2017
Legal address
CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
WILMINGTON, DE 19801
US
Headquarters
1000 Alfred Nobel Drive,
Hercules, CA 94547
US
Hercules, CA 94547
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||